Adlai Nortye Partners With Lilly And Merck KGaA To Evaluate AN4035 Combination In Solid Tumors

Adlai Nortye Group (ANL) partners with Eli Lilly (LLY) and Merck KGaA (MKKGY) to evaluate AN4035 in combination with cetuximab for solid tumors. The Phase I trial will assess safety and efficacy, with Lilly and Merck supplying the drug. ANL's stock closed at $10.88, up 3.40% in pre-market trading.

Original reporting
Published Oct 15, 2026, 1:04 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 15, 2026, 1:07 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$ANL
Bullish
high confidence
Mentioned
$ANL · $LLY · $MRK
Relevance
7/10
AlphAI data visualization · based on rttnews.com
Decision brief

The 30-second read

$ANLBullishMed
01

Why it matters

The collaboration validates the platform and may attract further partnership interest, but the true catalyst will be clinical data read‑outs.

02

Market read

First‑report of a multi‑partner Phase I study in RAS‑driven solid tumors; likely short‑term boost for ANL, neutral for partners.

03

What to watch

The trial's staggered start and lack of disclosed financial terms limit immediate upside.

Relevance 7/10Novelty 7/10Timing: pre‑market today

Background

Adlai Nortye Group is a micro‑cap biotech developing antibody‑drug conjugates. The AN4035 ADC targets CEACAM5 and delivers a pan‑RAS inhibitor.

Company-level read

Ticker impact

$ANLBullishHigh confidence
Context

Adlai Nortye Group announced a new clinical‑trial collaboration with Eli Lilly and Merck KGaA to test its ADC AN4035 in solid tumors.

Expected impact

likely upward pressure as investors price in the collaboration and potential future data read‑outs

Evidence & confidence

First‑report of a multi‑partner Phase I study; small‑cap biotech typically reacts positively to such validation.

$LLYNeutralMedium confidence
Context

Eli Lilly will supply cetuximab at no cost for U.S. sites in the ANL trial, expanding its oncology portfolio.

Expected impact

minimal impact; market already expects ongoing collaborations

Evidence & confidence

The deal is a supply agreement without financial commitment, typical for large pharma.

Market effects

Highlights growing interest in ADCs targeting RAS‑driven cancers, potentially benefiting peers in oncology biotech.

May draw attention to U.S., Australian and Chinese oncology trial sites.

Adds to the pipeline momentum for ADC technologies worldwide.

Counterpoint

If early‑stage data disappoint, the collaboration could become a liability for ANL, weighing on its valuation.

Key entities

  • Adlai Nortye Group

    Developer of AN4035 ADC

  • Eli Lilly and Company

    Supplier of cetuximab for U.S. trial sites

  • Merck KGaA

    Supplier of cetuximab for Australian and Chinese sites

Related articles

$PFEMedAI 8/10

Your Questions Answered: GLP-1 Deals, FDA Approvals, and Manufacturing Buildout

Pfizer and Blackstone Life Sciences agreed to co-fund berobenatide, a GLP-1 drug for weight management, with Blackstone covering up to $1.5B in development costs. Pfizer retains control. J&J acquired Ollin Biosciences for $2.2B, Lilly acquired Calytrix Bio for up to $1.5B, and Sanofi partnered with Seawolf Therapeutics. Gilead licensed obeldesivir to generic manufacturers for Ebola prevention. The FDA approved Novartis' Cosentyx for polymyalgia rheumatica and Roche's Wilserdly for breast cancer.

$LLYMed

Health Canada approves Eli Lilly’s GLP-1 pill for weight loss

Health Canada approved Eli Lilly's GLP-1 pill, Foundayo, for weight loss and Type 2 diabetes. The daily pill targets adults with obesity or overweight with related conditions. Eli Lilly expects pharmacy availability in January. Foundayo competes with Novo Nordisk's injectables and Rybelsus, a GLP-1 pill for diabetes only. The active ingredient, orforglipron, is a non-peptide GLP-1 receptor agonist.

$MRKMed

Merck scraps centerpiece of $2.7B ArQule buy after late-stage safety concerns

Merck (MRK) is discontinuing development of nemtabrutinib, an experimental BTK inhibitor acquired via its $2.7B purchase of ArQule, due to safety concerns identified in late-stage trials. The decision follows recommendations from a data monitoring committee and Merck's own review, leading to the halt of several Phase 3 studies in the BELLWAVE program. The drug was being evaluated for treating chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).

$SMMTMedAI 8/10

FDA publishes rejection letter for Summit drug; Nuvalent buyout pays more dividends for GSK

FDA rejected Summit Therapeutics' ivonescimab for lung cancer, citing insufficient benefits. Sellas Life Sciences' cancer vaccine showed 41% reduced death risk in a Phase 3 trial. GSK's Nelkarmi, acquired via Nuvalent buyout, gained FDA approval for lung cancer. AstraZeneca's gefurulimab was approved for myasthenia gravis. Eli Lilly partnered with Stipple Bio for cancer drugs, potentially worth $5.9B. Biogen invested $32M in Trimtech for neurodegenerative disease treatments.